

# **BIOCON GROUP**

## **FINANCIALS**

**Q3 FY 2006 vs Q3 FY 2005**

**9M FY 2006 vs 9M FY 2005**

## **FACT SHEET**

**BIOCON LIMITED (CONSOLIDATED)**

**PROFIT & LOSS STATEMENT**

(Rs. crores)

Particulars	Q3 FY 2006	Q3 FY 2005	Variance Q3 FY 06 vs Q3 FY 05	Nine Months ended FY 06	Nine Months ended FY 05	Variance FY 06 vs FY 05	Full Year ended March 31, 2005
<b><u>INCOME</u></b>							
Sales - Biopharmaceuticals	154	138	11%	445	425	5%	557
Sales - Enzymes	18	22	-14%	60	66	-8%	90
Contract Research	27	18	49%	69	47	45%	66
<b>Total Sales</b>	<b>199</b>	<b>178</b>	<b>12%</b>	<b>574</b>	<b>538</b>	<b>7%</b>	<b>713</b>
Other income	2	5		4	12		15
<b>Total Income / Revenues</b>	<b>201</b>	<b>183</b>	<b>10%</b>	<b>578</b>	<b>550</b>	<b>5%</b>	<b>728</b>
<b><u>EXPENDITURE</u></b>							
Material & Power costs	104	98		311	283		383
Staff costs	16	13		47	44		57
Other expenses	20	7		47	36		49
<b>Manufacturing &amp; other exps</b>	<b>140</b>	<b>118</b>	<b>19%</b>	<b>405</b>	<b>363</b>	<b>12%</b>	<b>489</b>
<b>PBDIT /EBIDTA</b>	<b>61</b>	<b>65</b>	<b>-6%</b>	<b>173</b>	<b>187</b>	<b>-7%</b>	<b>239</b>
Interest and finance charges	1	1		1	2		2
<b>PBDT</b>	<b>60</b>	<b>64</b>	<b>-6%</b>	<b>172</b>	<b>185</b>	<b>-7%</b>	<b>237</b>
Depreciation	7	6		22	16		22
<b>PBT</b>	<b>53</b>	<b>58</b>	<b>-9%</b>	<b>150</b>	<b>169</b>	<b>-11%</b>	<b>215</b>
Taxes	9	8		25	15		18
<b>PROFIT FOR THE PERIOD</b>	<b>44</b>	<b>50</b>	<b>-13%</b>	<b>125</b>	<b>154</b>	<b>-19%</b>	<b>197</b>
Add/(less): Minority interest	0	0		1	1		1
<b>PAT</b>	<b>44</b>	<b>50</b>	<b>-13%</b>	<b>126</b>	<b>155</b>	<b>-19%</b>	<b>198</b>
<b>EPS on paid-up capital (Rs)</b>	<b>4.4</b>	<b>5.0</b>		<b>12.6</b>	<b>15.5</b>		<b>19.8</b>

NOTE: The figures are rounded off to nearest crores, percentages are based on absolute numbers

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>BALANCE SHEET</b>		
<b>Particulars</b>	<b>As at 31-Dec-05</b>	<b>As at 31-Mar-05</b>
<b><u>SOURCES OF FUNDS</u></b>		
Share Capital	50	50
Reserves & Surplus	819	691
<b>Total Shareholder's Funds</b>	<b>869</b>	<b>741</b>
<b>Minority interest</b>	<b>2</b>	<b>1</b>
<b>Deferred Tax Liability</b>	<b>21</b>	<b>23</b>
Secured Loans	31	49
Unsecured Loans	35	27
<b>Total Loan Funds</b>	<b>66</b>	<b>76</b>
<b>Total</b>	<b>958</b>	<b>841</b>
<b><u>APPLICATION OF FUNDS</u></b>		
<b>Fixed Assets (Net)</b>	<b>783</b>	<b>578</b>
<b>Investments</b>	<b>83</b>	<b>235</b>
Inventories	117	74
Sundry debtors	218	183
Cash and bank balances	2	3
Loans and advances	23	17
<b>Total Current Assets, Loans &amp; Advances</b>	<b>360</b>	<b>277</b>
<b>Less: Current liabilities and provisions</b>	<b>268</b>	<b>249</b>
<b>Net Current assets</b>	<b>92</b>	<b>28</b>
<b>Total</b>	<b>958</b>	<b>841</b>

<b>BIOCON LIMITED (CONSOLIDATED)</b>		
<b>STATEMENT OF CASH FLOWS</b>		<i>(Rs. crores)</i>
<b>Particulars</b>	<b>Nine months ended Dec 31, 2005</b>	<b>Full Year ended March 31, 2005</b>
<b><u>I. Cash Flow from Operating Activities</u></b>		
Net profit before tax	150	215
<b>Less/Add: non-cash items/ items required separately</b>		
Depreciation	22	22
Others	(0)	(10)
Changes in working capital and other provisions	(68)	(43)
Cash generated from operations	104	184
Tax paid (net of refunds)	(16)	(12)
<b>Net Cash provided by operating activities</b>	<b>88</b>	<b>172</b>
<b><u>II. Cash Flow from Investing Activities</u></b>		
Fixed Assets	(238)	(285)
Change in minority Interest	2	(1)
Interest / dividend received	4	13
Investments	152	(213)
<b>Net cash used for investing activities</b>	<b>(80)</b>	<b>(485)</b>
<b><u>III. Cash Flows from Financing Activities</u></b>		
Proceeds from issuance of share capital (net of expenses)	0	0
Borrowings and other financing activities	(11)	(2)
<b>Net Cash provided/(used) for financing activities</b>	<b>(11)</b>	<b>(2)</b>
<b><u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u></b>		
	(3)	(315)
<b><u>V. Cash &amp; Cash Eq. at the beginning of the year</u></b>	<b>3</b>	<b>318</b>
<b><u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u></b>	<b>2</b>	<b>0</b>
<b><u>VII. Cash and Cash Eq. at the end of the year (IV+V+VI)</u></b>	<b>2</b>	<b>3</b>